Manages central diabetes insipidus. ANDA 74830, held by Bausch Health. Desmopressin Acetate.
As of Nov 21, 2026, ANDA 74830 (Desmopressin Acetate), held by Bausch Health, was first approved by FDA on Jan 25, 1999, with 9 approved supplements and 0 published complete response letters.
Desmopressin nasal spray solution is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in adults and pediatric patients 4 years of age and older. Limitations of Use: Desmopressin nasal spray solution is not indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 25, 1999 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desmopressin Acetate0.01MG/SPRAY · spray, metered;nasal | Desmopressin Acetate | Discontinued |
| Aug 18, 2021 | Supplement 22Labeling · Standard review | Approved | None posted |
| Aug 18, 2021 | Supplement 23Labeling · Standard review | Approved | None posted |
| Apr 2, 2015 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jan 14, 2015 | Supplement 17Manufacturing | Approved | None posted |
| Apr 25, 2008 | Supplement 13Labeling | Approved | None posted |
| Sep 21, 2004 | Supplement 8Labeling | Approved | None posted |
| Apr 28, 2000 | Supplement 2Manufacturing | Approved | None posted |
| Oct 25, 1999 | Supplement 4Labeling | Approved | None posted |
| Sep 13, 1999 | Supplement 1Manufacturing | Approved | None posted |
| Jan 25, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters